Predictive value of the CLL ‐ IPI in CLL patients receiving chemo‐immunotherapy as first‐line treatment
Year: 2018
Type: article
Abstract: An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016. This article is protected by copyright. All rights reserved.
Source: European Journal Of Haematology
DOI: 10.1111/ejh.13149
Authors: Massimo Gentile, Tait D. Shanafelt, Francesca Romana Mauro, Gianluigi Reda, Davide Rossi, Luca Laurenti, Maria Ilaria Del Principe, Giovanna Cutrona, Ilaria Angeletti, Marta Coscia, Yair Herishanu, Annalisa Chiarenza, Stefano Molica, Stefania Ciolli, Neta Goldschmidt, Francesco Angrilli, Annamaria Giordano, Angela Rago, Osnat Bairey, Giovanni Tripepi, Kari G. Chaffee, Parikh A. Sameer, Ernesto Vigna, Katja Zirlik, Lev Shvidel, Idanna Innocenti, Anna Grazia Recchia, Francesco Di Raimondo, Giovanni Del Poeta, Agostino Cortelezzi, Antonino Neri, Manlio Ferrarini, Gianluca Gaidano, Neil E. Kay, Aaron Polliack, Robin Foà, Fortunato Morabito
Institutions: Ospedale Annunziata di Cosenza, Stanford Medicine, Stanford University, Sapienza University of Rome, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Institute of Oncology Research, Istituto Oncologico della Svizzera Italiana, University of Rome Tor Vergata, Ospedale Policlinico San Martino, Azienda Ospedaliera S.Maria, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, University of Turin, Tel Aviv University, University of Catania, Ferrarotto Hospital, Azienda Ospedaliera Pugliese Ciaccio, University of Florence, Hebrew University of Jerusalem, Hadassah Medical Center, Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari, Ospedale Santa Maria Goretti, Rabin Medical Center, National Research Council, Mayo Clinic, University of Freiburg, University Medical Center Freiburg, Kaplan Medical Center, Azienda Sanitaria Provinciale di Cosenza, Azienda Ospedaliero Universitaria Maggiore della Carita
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2883427102